Neuren Pharmaceuticals Limited (NEU.AX)
AUD 10.39
(-1.33%)
AUD 10.39
(-1.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 225.96 Million AUD | 12582.96% |
| 2022 | -1.59 Million AUD | 86.04% |
| 2021 | -11.43 Million AUD | -19.99% |
| 2020 | -9.52 Million AUD | 17.67% |
| 2019 | -11.57 Million AUD | -298.99% |
| 2018 | 5.81 Million AUD | 186.74% |
| 2017 | -6.7 Million AUD | 55.8% |
| 2016 | -15.16 Million AUD | 12.09% |
| 2015 | -17.25 Million AUD | -77.45% |
| 2014 | -9.72 Million AUD | -2.88% |
| 2013 | -9.44 Million AUD | 0.3% |
| 2012 | -9.47 Million AUD | -100.18% |
| 2011 | -4.73 Million AUD | 5.09% |
| 2010 | -4.98 Million AUD | -3904.59% |
| 2009 | 131.13 Thousand AUD | 101.39% |
| 2008 | -9.43 Million AUD | 21.98% |
| 2007 | -12.09 Million AUD | 0.71% |
| 2006 | -12.17 Million AUD | -15.82% |
| 2005 | -10.51 Million AUD | -38.26% |
| 2004 | -7.6 Million AUD | -427.49% |
| 2003 | 2.32 Million AUD | 45.47% |
| 2002 | 1.59 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -13.82 Million AUD | 0.0% |
| 2023 Q2 | 48.14 Million AUD | 0.0% |
| 2023 FY | 199.22 Million AUD | 12582.96% |
| 2023 Q4 | 151.08 Million AUD | 0.0% |
| 2022 Q4 | 5.74 Million AUD | 0.0% |
| 2022 FY | -1.59 Million AUD | 86.04% |
| 2022 Q2 | -7.33 Million AUD | 0.0% |
| 2021 Q2 | -8.19 Million AUD | 0.0% |
| 2021 FY | -11.43 Million AUD | -19.99% |
| 2021 Q4 | -3.23 Million AUD | 0.0% |
| 2020 FY | -9.52 Million AUD | 17.67% |
| 2020 Q2 | -5.31 Million AUD | 0.0% |
| 2020 Q4 | -4.21 Million AUD | 0.0% |
| 2019 FY | -11.57 Million AUD | -298.99% |
| 2019 Q2 | -7.9 Million AUD | 0.0% |
| 2019 Q4 | -3.66 Million AUD | 0.0% |
| 2018 Q4 | 9.71 Million AUD | 0.0% |
| 2018 FY | 5.81 Million AUD | 186.74% |
| 2018 Q2 | -3.89 Million AUD | 0.0% |
| 2017 Q2 | -3.47 Million AUD | 0.0% |
| 2017 Q4 | -2.6 Million AUD | 0.0% |
| 2017 FY | -6.7 Million AUD | 55.8% |
| 2016 Q2 | -8.15 Million AUD | 0.0% |
| 2016 FY | -15.16 Million AUD | 12.09% |
| 2016 Q4 | -3.86 Million AUD | 0.0% |
| 2015 Q4 | -9.05 Million AUD | 0.0% |
| 2015 FY | -17.25 Million AUD | -77.45% |
| 2015 Q2 | -6.52 Million AUD | 0.0% |
| 2014 Q2 | -4.44 Million AUD | 0.0% |
| 2014 Q4 | -5.27 Million AUD | 0.0% |
| 2014 FY | -9.72 Million AUD | -2.88% |
| 2013 Q4 | -3.7 Million AUD | -31.23% |
| 2013 FY | -9.44 Million AUD | 0.3% |
| 2013 Q3 | -2.82 Million AUD | 2.9% |
| 2013 Q2 | -2.9 Million AUD | -2.98% |
| 2013 Q1 | -2.82 Million AUD | 0.0% |
| 2012 Q2 | -1.27 Million AUD | 0.0% |
| 2012 Q3 | -1.27 Million AUD | 0.0% |
| 2012 FY | -9.47 Million AUD | -100.18% |
| 2012 Q4 | -2.82 Million AUD | -121.82% |
| 2012 Q1 | -1.27 Million AUD | 0.0% |
| 2011 Q3 | -1.16 Million AUD | 0.0% |
| 2011 Q1 | -1.16 Million AUD | 0.0% |
| 2011 Q2 | -1.16 Million AUD | 0.0% |
| 2011 FY | -4.73 Million AUD | 5.09% |
| 2011 Q4 | -1.27 Million AUD | -9.67% |
| 2010 Q3 | -1.22 Million AUD | 0.0% |
| 2010 Q1 | -1.22 Million AUD | 0.0% |
| 2010 Q4 | -1.16 Million AUD | 5.06% |
| 2010 FY | -4.98 Million AUD | -3904.59% |
| 2010 Q2 | -1.22 Million AUD | 0.0% |
| 2009 Q2 | 25.49 Thousand AUD | 0.0% |
| 2009 Q4 | -1.22 Million AUD | -4896.45% |
| 2009 Q1 | 25.49 Thousand AUD | 0.0% |
| 2009 Q3 | 25.49 Thousand AUD | 0.0% |
| 2009 FY | 131.13 Thousand AUD | 101.39% |
| 2008 Q2 | -3.83 Million AUD | 0.0% |
| 2008 Q3 | -3.83 Million AUD | 0.0% |
| 2008 Q4 | 25.49 Thousand AUD | 100.67% |
| 2008 FY | -9.43 Million AUD | 21.98% |
| 2008 Q1 | -3.83 Million AUD | 0.0% |
| 2007 Q3 | -3.02 Million AUD | 0.0% |
| 2007 Q1 | -3.02 Million AUD | 0.0% |
| 2007 FY | -12.09 Million AUD | 0.71% |
| 2007 Q4 | -3.83 Million AUD | -26.8% |
| 2007 Q2 | -3.02 Million AUD | 0.0% |
| 2006 Q4 | -3.02 Million AUD | -19.53% |
| 2006 Q3 | -2.52 Million AUD | 0.0% |
| 2006 FY | -12.17 Million AUD | -15.82% |
| 2006 Q1 | -2.52 Million AUD | 0.0% |
| 2006 Q2 | -2.52 Million AUD | 0.0% |
| 2005 Q1 | -2.07 Million AUD | 0.0% |
| 2005 Q2 | -2.07 Million AUD | 0.0% |
| 2005 Q3 | -2.07 Million AUD | 0.0% |
| 2005 Q4 | -2.52 Million AUD | -22.02% |
| 2005 FY | -10.51 Million AUD | -38.26% |
| 2004 Q2 | -2.84 Million AUD | 0.0% |
| 2004 FY | -7.6 Million AUD | -427.49% |
| 2004 Q4 | -2.07 Million AUD | 27.2% |
| 2004 Q1 | -2.84 Million AUD | 0.0% |
| 2004 Q3 | -2.84 Million AUD | 0.0% |
| 2003 Q1 | -2.82 Million AUD | 0.0% |
| 2003 Q3 | -2.82 Million AUD | 0.0% |
| 2003 FY | 2.32 Million AUD | 45.47% |
| 2003 Q4 | -2.84 Million AUD | -0.83% |
| 2003 Q2 | -2.82 Million AUD | 0.0% |
| 2002 FY | 1.59 Million AUD | 0.0% |
| 2002 Q1 | -2.72 Million AUD | 0.0% |
| 2002 Q2 | -2.72 Million AUD | 0.0% |
| 2002 Q3 | -2.72 Million AUD | 0.0% |
| 2002 Q4 | -2.82 Million AUD | -3.46% |
| 2001 Q4 | -2.72 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | 4394.555% |
| Acrux Limited | -9.83 Million AUD | 2397.763% |
| Actinogen Medical Limited | -12.83 Million AUD | 1859.967% |
| AnteoTech Limited | -11.72 Million AUD | 2026.918% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 4084.374% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 3241.395% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 15586.109% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 1252.767% |
| Amplia Therapeutics Limited | -4.42 Million AUD | 5206.518% |
| Avecho Biotechnology Limited | -4.58 Million AUD | 5023.789% |
| Bio-Gene Technology Limited | -3.06 Million AUD | 7478.44% |
| Biome Australia Limited | -1.91 Million AUD | 11910.437% |
| Biotron Limited | -5.15 Million AUD | 4486.615% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 1637.171% |
| BTC Health Limited | 1.05 Million AUD | -21312.374% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 1935.645% |
| CSL Limited | 5.64 Billion AUD | 96.0% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 604.372% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | -359.757% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 2665.44% |
| Dimerix Limited | -25.05 Million AUD | 1001.692% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | -2225.534% |
| Hexima Limited | -1 Million AUD | 22500.198% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | 7962.882% |
| Immuron Limited | -5.8 Million AUD | 3995.146% |
| Immutep Limited | -44.93 Million AUD | 602.841% |
| Imugene Limited | -140.93 Million AUD | 260.336% |
| Invex Therapeutics Ltd | -2.13 Million AUD | 10690.511% |
| Memphasys Limited | -2.7 Million AUD | 8456.583% |
| Nanollose Limited | -1.24 Million AUD | 18179.491% |
| Noxopharm Limited | -7.53 Million AUD | 3098.831% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | 11087.377% |
| Nyrada Inc. | -4.56 Million AUD | 5054.948% |
| Orthocell Limited | -11.68 Million AUD | 2034.421% |
| PharmAust Limited | -6.65 Million AUD | 3493.521% |
| Patrys Limited | -3.53 Million AUD | 6484.64% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 447.035% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 3224.67% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 3244.292% |
| PYC Therapeutics Limited | -38.85 Million AUD | 681.519% |
| Race Oncology Limited | -13.38 Million AUD | 1788.734% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 578.633% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 1124.713% |
| Starpharma Holdings Limited | -15.15 Million AUD | 1590.613% |
| Telix Pharmaceuticals Limited | - AUD | -Infinity% |
| Tissue Repair Ltd | -4.87 Million AUD | 4734.214% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 3905.208% |